RANKL — Drug Target
All drugs that target RANKL — marketed and clinical-stage. Includes 4 drug classes acting on this target.
Drug classes
RANK Ligand Inhibitor [EPC] · RANKL inhibitor · Denosumab · Monoclonal antibody
Marketed (1)
- BONCRESA · AMNEAL PHARMS LLC · RANK Ligand Inhibitor [EPC] · Other
Denosumab binds to RANKL, preventing it from activating RANK on osteoclasts, reducing bone resorption and increasing bone mass.
Phase 3 pipeline (6)
- ABP 959 · Amgen · RANKL inhibitor · Bone metabolism / Oncology
ABP 959 is a RANKL inhibitor that blocks osteoclast activation and bone resorption. - ABP 938 · Amgen · RANKL inhibitor · Bone metabolism / Osteoporosis
ABP 938 is a RANKL inhibitor that blocks osteoclast activation and bone resorption. - ABP 234 · Amgen · RANKL inhibitor · Bone metabolism / Oncology
ABP 234 is a RANKL inhibitor that blocks osteoclast activation and bone resorption. - US-licensed Prolia (Amgen) · Fresenius Kabi SwissBioSim GmbH · Denosumab · Osteoporosis
Prolia is a human monoclonal antibody that targets RANKL, a protein involved in bone resorption. - Prolia® (Denosumab) · Samsung Bioepis Co., Ltd. · Monoclonal antibody · Osteoporosis, Bone-related disorders
Prolia works by binding to RANKL, a protein involved in the formation and activation of osteoclasts, which are cells that break down bone. - US-licensed Prolia · Celltrion · Denosumab · Osteoporosis
Prolia is a human monoclonal antibody that targets RANKL, a protein involved in bone resorption.
Phase 2 pipeline (1)
- AMG 162 - Prolia · Amgen · RANKL inhibitor · Bone disorders
AMG 162, also known as Prolia, is a human monoclonal antibody that targets RANKL, a protein involved in bone resorption.
Phase 1 pipeline (1)
- Anti-RANKL Monoclonal Antibody · Shanghai JMT-Bio Inc. · Monoclonal antibody · Osteoporosis
Inhibits RANKL